Zenas BioPharma Presents New Obexelimab Data in IgG4-Related Disease
Phase 3 INDIGO open-label extension findings showed sustained clinical activity. Additional secondary-endpoint analyses found significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52.